A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

Phase 3 Completed 93 enrolled Tonix Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label extension study (TNX-CY-P303).

Timeline

Start: 2018-04-19
Primary completion: 2019-09-30
Completion: 2019-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	cyclobenzaprine	Small molecule	5.6 mg	Other

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

Summary

Timeline

Drugs

Indications